Potential treatment of Parkinson’s disease with omega-3 polyunsaturated fatty acids

References

• Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017: 317013.
   Web of Science ®Google Scholar
• Winkler S, Hagenah J, Lincoln S, Heckman M, Haugarvoll K, Lohmann-Hedrich K, et al. α-Synuclein and Parkinson disease susceptibility. Neurology. 2007;69(18):1745–50.
   PubMed Web of Science ®Google Scholar
• Xia L, Guo D, Chen B. Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes. Exp Ther Med. 2017;14(6):5569–75.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Sango K, Wada K, Nagai Y. Pathological role of lipid interaction with alpha-synuclein in Parkinson's disease. Neurochem Int. 2018;119:97–106.
   PubMed Web of Science ®Google Scholar
• Yu SY, Cao CJ, Zuo LJ, Chen ZJ, Lian TH, Wang F, et al. Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra: a cross-sectional study. BMC Neurol. 2018;18(1):9.
   PubMed Web of Science ®Google Scholar
• Polito L, Greco A, Seripa D. Genetic profile, environmental exposure, and their interaction in Parkinson’s disease. Parkinson’s Disease. 2016;2016:1–9.
   Web of Science ®Google Scholar
• Gordon PH, Mehal JM, Holman RC, Rowland AS, Cheek JE. Parkinson's disease among American Indians and Alaska natives: a nationwide prevalence study. Mov Disord. 2012;27(11):1456–9.
   PubMed Web of Science ®Google Scholar
• Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. The relation between alpha-synuclein and microglia in Parkinson's disease: recent developments. Neuroscience. 2015;302:47–58.
   PubMed Web of Science ®Google Scholar
• Camilleri A, Vassallo N. The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease. CNS Neurosci Ther. 2014;20(7):591–602.
   PubMed Web of Science ®Google Scholar
• Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. J Neurosci Res. 2018;96(3):379–90.
   PubMed Web of Science ®Google Scholar
• Jiang T, Sun Q, Chen S. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. Prog Neurobiol. 2016;147:1–19.
   PubMed Web of Science ®Google Scholar
• Seidl SE, Santiago JA, Bilyk H, Potashkin JA. The emerging role of nutrition in Parkinson's disease. Front Aging Neurosci. 2014;6:1–14. Article number 36.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38(8):1285–91.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:1–9. Article number 19.
   PubMed Web of Science ®Google Scholar
• Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLos One. 2008;3(1):e1376.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(supplement 1):S210–12.
   PubMed Web of Science ®Google Scholar
• Joers V, Tansey MG, Mulas G, Carta AR. Microglial phenotypes in Parkinson’s disease and animal models of the disease. Prog Neurobiol. 2017;155:57–75.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4(1):19.
   PubMed Web of Science ®Google Scholar
• Hernandes M S, Britto L RG. NADPH oxidase and neurodegeneration. Curr Neuropharmacol. 2012;10(4):321–7.
   PubMed Web of Science ®Google Scholar
• Knott C, Stern G, Wilkin G. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2. Mol Cell Neurosci. 2000;16(6):724–39.
   PubMed Web of Science ®Google Scholar
• Lefkowitz DL, Lefkowitz SS. Microglia and myeloperoxidase: a deadly partnership in neurodegenerative disease. Free Radical Biol Med. 2008;45(5):726–31.
   PubMed Web of Science ®Google Scholar
• Yao L, Kan EM, Lu J, Hao A, Dheen ST, Kaur C, et al. Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: role of TLR4 in hypoxic microglia. J Neuroinflamm. 2013;10(1):785.
   Web of Science ®Google Scholar
• Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflamm. 2014;11(1):98.
   PubMed Web of Science ®Google Scholar
• Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53(2):1181–94.
   PubMed Web of Science ®Google Scholar
• Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–7.
   PubMed Web of Science ®Google Scholar
• Li K, Li J, Zheng J, Qin S. Reactive astrocytes in neurodegenerative diseases. Aging Dis. 2019;10(3):664.
   PubMed Web of Science ®Google Scholar
• Cekanaviciute E, Buckwalter MS. Astrocytes: integrative regulators of neuroinflammation in stroke and other neurological diseases. Neurotherapeutics. 2016;13(4):685–701.
   PubMed Web of Science ®Google Scholar
• Park J-S, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinson’s disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21.
   PubMed Web of Science ®Google Scholar
• Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016;139:216–31.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr. 2004;36(4):375–9.
   PubMed Web of Science ®Google Scholar
• Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta (BBA) – Mol Basis Disease. 2010;1802(1):29–44.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Himeda T, Araki T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med Sci Monit. 2005;11(1):Ra17–23.
   PubMed Web of Science ®Google Scholar
• Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. IUBMB Life. 2001;52(3-5):135–41.
   PubMed Web of Science ®Google Scholar
• Tan W, Xue-bin C, Tian Z, Xiao-wu C, Pei-pei H, Zhi-bin C, et al. Effects of simvastatin on the expression of inducible nitric oxide synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of Parkinson disease. Int J Neurosci. 2016;126(3):278–86.
   PubMed Web of Science ®Google Scholar
• Dou F, Chu X, Zhang B, Liang L, Lu G, Ding J, et al. Erib targeted inhibition of microglia activity attenuates MPP+ induced DA neuron injury through the NF-κB signaling pathway. Mol Brain. 2018;11(1):1–11.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787.
   PubMed Web of Science ®Google Scholar
• Bonifati V. Autosomal recessive parkinsonism. Parkinsonism Relat Disord. 2012;18:S4–S6.
   PubMedGoogle Scholar
• Yang N, Zhao Y, Liu Z, Zhang R, He Y, Zhou Y, et al. Systematically analyzing rare variants of autosomal-dominant genes for sporadic Parkinson's disease in a Chinese cohort. Neurobiol Aging. 2019;76215:e211–215. e217.
   Google Scholar
• Puspita L, Chung SY, Shim J-w. Oxidative stress and cellular pathologies in Parkinson’s disease. Mol Brain. 2017;10(1):53.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.
   PubMed Web of Science ®Google Scholar
• Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013;3(4):461–91.
   PubMedGoogle Scholar
• Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimer's Dis. 2006;10(1):59–73.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang W, Hoppel C, Liu J, Zhu X. Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochim Biophys Acta (BBA) – Mol Basis Dis. 2017;1863(11):2791–5.
   PubMed Web of Science ®Google Scholar
• Lim K-L, Tan JM. Role of the ubiquitin proteasome system in Parkinson's disease. BMC Biochem. 2007;8(1):S13.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol. 2005;191(Suppl ):1S17–27.
   Google Scholar
• Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. Mov Disord. 2006;21(11):1806–23.
   PubMed Web of Science ®Google Scholar
• Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol Neurodegener. 2019;14(1):35.
   PubMed Web of Science ®Google Scholar
• Ellis JM, Fell MJ. Current approaches to the treatment of Parkinson’s disease. Bioorg Med Chem Lett. 2017;27(18):4247–55.
   PubMed Web of Science ®Google Scholar
• Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016;139(Suppl):1325–337.
   Google Scholar
• Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008;4(4):743–57.
   PubMedGoogle Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–83.
   PubMed Web of Science ®Google Scholar
• Lee H, Pienaar IS. Disruption of the blood-brain barrier in Parkinson’s disease: curse or route to a cure. Front Biosci (Landmark Ed). 2014;19:272–80.
   PubMed Web of Science ®Google Scholar
• deSouza RM, Moro E, Lang AE, Schapira AH. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol. 2013;73(5):565–75.
   PubMed Web of Science ®Google Scholar
• Chan DT, Zhu XL, Yeung JH, Mok VC, Wong E, Lau C, et al. Complications of deep brain stimulation: a collective review. Asian J Surg. 2009;32(4):258–63.
   PubMed Web of Science ®Google Scholar
• Abedi E, Sahari MA. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci Nutr. 2014;2(5):443–63.
   PubMedGoogle Scholar
• Bousquet M, Calon F, Cicchetti F. Impact of omega-3 fatty acids in Parkinson's disease. Ageing Res Rev. 2011;10(4):453–63.
   PubMed Web of Science ®Google Scholar
• Calon F, Cicchetti F. Can we prevent Parkinson’s disease with n-3 polyunsaturated fatty acids? Future Lipidol. 2008;3(2):133–7.
   Web of Science ®Google Scholar
• Xia R, Mao Z-H. Progression of motor symptoms in Parkinson’s disease. Neurosci Bull. 2012;28(1):39–48.
   PubMed Web of Science ®Google Scholar
• Luchtman DW, Meng Q, Song C. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav Brain Res. 2012;226(2):386–96.
   PubMed Web of Science ®Google Scholar
• Tanriover G, Seval-Celik Y, Ozsoy O, Akkoyunlu G, Savcioglu F, Hacioglu G, et al. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease. Folia Histochem Cytobiol. 2010;48(3):434–41.
   PubMed Web of Science ®Google Scholar
• Delattre AM, Kiss A, Szawka RE, Anselmo-Franci JA, Bagatini PB, Xavier LL, et al. Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease. Neurosci Res. 2010;66(3):256–64.
   PubMed Web of Science ®Google Scholar
• Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res. 2008;62(3):206–9.
   PubMed Web of Science ®Google Scholar
• Orr SK, Bazinet RP. The emerging role of docosahexaenoic acid in neuroinflammation. Curr Opin Investig Drugs. 2008;9(7):735–43.
   PubMedGoogle Scholar
• Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflamm. 2005;2:1–8. Article number 14.
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2004;10(Suppl):1S3–7.
   Google Scholar
• Barcia C, Fernandez Barreiro A, Poza M, Herrero MT. Parkinson's disease and inflammatory changes. Neurotox Res. 2003;5(6):411–8.
   PubMed Web of Science ®Google Scholar
• Ji A, Diao H, Wang X, Yang R, Zhang J, Luo W, et al. n-3 polyunsaturated fatty acids inhibit lipopolysaccharide-induced microglial activation and dopaminergic injury in rats. Neurotoxicology. 2012;33(4):780–8.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhen J, Lu Z. Synergetic neuroprotective effect of docosahexaenoic acid and aspirin in SH-Y5Y by inhibiting miR-21 and activating RXRα and PPARα. DNA Cell Biol. 2017;36(6):482–9.
   PubMed Web of Science ®Google Scholar
• Meng Q, Luchtman DW, El Bahh B, Zidichouski JA, Yang J, Song C. Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. Eur J Pharmacol. 2010;649(1–3):127–34.
   PubMed Web of Science ®Google Scholar
• Luchtman DW, Meng Q, Wang X, Shao D, Song C. Omega-3 fatty acid eicospentaenoic acid attenuates MPP+-induced neurodegeneration in fully differentiated human SH-SY 5Y and primary mesencephalic cells. J Neurochem. 2013;124(6):855–68.
   PubMed Web of Science ®Google Scholar
• Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem. 2003;278(17):14677–87.
   PubMed Web of Science ®Google Scholar
• Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 2005;15(2):159–66.
   PubMed Web of Science ®Google Scholar
• Hernando S, Requejo C, Herran E, Ruiz-Ortega JA, Morera-Herreras T, Lafuente JV, et al. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: the role of glia and NRf2 regulation. Neurobiol Dis. 2019;121:252–62.
   PubMed Web of Science ®Google Scholar
• Xu J, Gao X, Yang C, Chen L, Chen Z. Resolvin D1 attenuates Mpp+-induced Parkinson disease via inhibiting inflammation in PC12 cells. Med Sci Monit: Int Med J Exp Clin Res. 2017;23:2684–91.
   Google Scholar
• Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003;278(44):43807–17.
   PubMed Web of Science ®Google Scholar
• Cardoso HD, dos Santos Junior EF, de Santana DF, Gonçalves-Pimentel C, Angelim MK, Isaac AR, et al. Omega-3 deficiency and neurodegeneration in the substantia nigra: involvement of increased nitric oxide production and reduced BDNF expression. Biochim Biophys Acta (BBA) – General Subjects. 2014;1840(6):1902–12.
   PubMed Web of Science ®Google Scholar
• Mori MA, Delattre AM, Carabelli B, Pudell C, Bortolanza M, Staziaki PV, et al. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase. Nutr Neurosci. 2018;21(5):341–51.
   PubMed Web of Science ®Google Scholar
• Mounsey RB, Teismann P. Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis. 2010;2011:1–18. Article number 617472.
   Web of Science ®Google Scholar
• Ramonet D, Perier C, Recasens A, Dehay B, Bove J, Costa V, et al. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ. 2013;20(1):77–85.
   PubMed Web of Science ®Google Scholar
• Hu Q, Wang G. Mitochondrial dysfunction in Parkinson’s disease. Transl Neurodegener. 2016;5(1):14.
   PubMed Web of Science ®Google Scholar
• Kim H-Y, Akbar M, Kim K-Y. Inhibition of neuronal apoptosis by polyunsaturated fatty acids. J Mol Neurosci. 2001;16(2-3):223–7.
   PubMed Web of Science ®Google Scholar
• Kim H-Y, Akbar M, Lau A, Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22: 6n-3) role of phosphatidylserine in antiapoptotic effect. J Biol Chem. 2000;275(45):35215–23.
   PubMed Web of Science ®Google Scholar
• Wu Y, Tada M, Takahata K, Tomizawa K, Matsui H. Inhibitory effect of polyunsaturated fatty acids on apoptosis induced by etoposide, okadaic acid and AraC in Neuro2a cells. Acta Med Okayama. 2007;61(3):147–52.
   PubMed Web of Science ®Google Scholar
• Hacioglu G, Seval-Celik Y, Tanriover G, Ozsoy O, Saka-Topcuoglu E, Balkan S, et al. Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease. Folia Histochem Cytobiol. 2012;50(2):228–38.
   PubMed Web of Science ®Google Scholar
• Yakunin E, Loeb V, Kisos H, Biala Y, Yehuda S, Yaari Y, et al. Α-synuclein neuropathology is controlled by Nuclear Hormone receptors and enhanced by docosahexaenoic acid in A Mouse model for Parkinson's disease. Brain Pathol. 2012;22(3):280–94.
   PubMed Web of Science ®Google Scholar
• Coulombe K, Kerdiles O, Tremblay C, Emond V, Lebel M, Boulianne A-S, et al. Impact of DHA intake in a mouse model of synucleinopathy. Exp Neurol. 2018;301:39–49.
   PubMed Web of Science ®Google Scholar
• Muntané G, Janué A, Fernandez N, Odena MA, Oliveira E, Boluda S, et al. Modification of brain lipids but not phenotype in α-synucleinopathy transgenic mice by long-term dietary n-3 fatty acids. Neurochem Int. 2010;56(2):318–28.
   PubMed Web of Science ®Google Scholar
• Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525–42.
   PubMed Web of Science ®Google Scholar
• Ådén E, Carlsson M, Poortvliet E, Stenlund H, Linder J, Edström M, et al. Dietary intake and olfactory function in patients with newly diagnosed Parkinson's disease: a case-control study. Nutr Neurosci. 2011;14(1):25–31.
   PubMed Web of Science ®Google Scholar
• De Lau L, Bornebroek M, Witteman J, Hofman A, Koudstaal PJ, Breteler M. Dietary fatty acids and the risk of Parkinson disease the Rotterdam study. Neurology. 2005;64(12):2040–5.
   PubMed Web of Science ®Google Scholar
• da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss Á, Andreatini R, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111(2–3):351–9.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, Tsuboi Y, et al. Dietary fat intake and risk of Parkinson's disease: a case-control study in Japan. J Neurol Sci. 2010;288(1–2):117–22.
   PubMed Web of Science ®Google Scholar
• Taghizadeh M, Tamtaji OR, Dadgostar E, Kakhaki RD, Bahmani F, Abolhassani J, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Neurochem Int. 2017;108:183–9.
   PubMed Web of Science ®Google Scholar
• Hatami A, Zhu C, Relaño-Gines A, Elias C, Galstyan A, Jun M, et al. Deuterium-reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington's disease. FEBS J. 2018;285(16):3002–12.
   PubMed Web of Science ®Google Scholar
• Lee LK, Shahar S, Chin A-V, Yusoff NAM. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology. 2013;225(3):605–12.
   PubMed Web of Science ®Google Scholar
• Cazzola R, Rondanelli M, Faliva M, Cestaro B. Effects of DHA-phospholipids, melatonin and tryptophan supplementation on erythrocyte membrane physico-chemical properties in elderly patients suffering from mild cognitive impairment. Exp Gerontol. 2012;47(12):974–8.
   PubMed Web of Science ®Google Scholar
• Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189–96.
   PubMed Web of Science ®Google Scholar
• Martínez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvadó J, San Julián B, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318–25.
   PubMed Web of Science ®Google Scholar
• Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445(7128):643.
   PubMed Web of Science ®Google Scholar
• Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 2007;317(5842):1220–4.
   PubMed Web of Science ®Google Scholar
• Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. J Neurol. 2019;266:1927–36.
   PubMed Web of Science ®Google Scholar
• Dissanayaka NN, Torbey E, Pachana NA. Anxiety rating scales in Parkinson's disease: a critical review updating recent literature. Int Psychogeriatr. 2015;27(11):1777–84.
   PubMed Web of Science ®Google Scholar
• Qutubuddin AA, Pegg PO, Cifu DX, Brown R, McNamee S, Carne W. Validating the Berg Balance Scale for patients with Parkinson’s disease: a key to rehabilitation evaluation. Arch Phys Med Rehabil. 2005;86(4):789–92.
   PubMed Web of Science ®Google Scholar